JP2008546687A5 - - Google Patents

Download PDF

Info

Publication number
JP2008546687A5
JP2008546687A5 JP2008516813A JP2008516813A JP2008546687A5 JP 2008546687 A5 JP2008546687 A5 JP 2008546687A5 JP 2008516813 A JP2008516813 A JP 2008516813A JP 2008516813 A JP2008516813 A JP 2008516813A JP 2008546687 A5 JP2008546687 A5 JP 2008546687A5
Authority
JP
Japan
Prior art keywords
tumor
antigen
protein
immunotherapeutic
tuaa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008516813A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008546687A (ja
Filing date
Publication date
Priority claimed from US11/155,288 external-priority patent/US20060008468A1/en
Application filed filed Critical
Publication of JP2008546687A publication Critical patent/JP2008546687A/ja
Publication of JP2008546687A5 publication Critical patent/JP2008546687A5/ja
Pending legal-status Critical Current

Links

JP2008516813A 2005-06-17 2005-12-29 種々の型の癌の診断における腫瘍関連抗原の組合せ Pending JP2008546687A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/155,288 US20060008468A1 (en) 2004-06-17 2005-06-17 Combinations of tumor-associated antigens in diagnostics for various types of cancers
PCT/US2005/047443 WO2007001476A1 (en) 2005-06-17 2005-12-29 Combinations of tumor-associated antigens in diagnostics for various types of cancer

Publications (2)

Publication Number Publication Date
JP2008546687A JP2008546687A (ja) 2008-12-25
JP2008546687A5 true JP2008546687A5 (https=) 2009-02-26

Family

ID=36636429

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008516813A Pending JP2008546687A (ja) 2005-06-17 2005-12-29 種々の型の癌の診断における腫瘍関連抗原の組合せ

Country Status (6)

Country Link
US (2) US20060008468A1 (https=)
EP (1) EP1896854A1 (https=)
JP (1) JP2008546687A (https=)
CA (1) CA2612512A1 (https=)
MX (1) MX2007015946A (https=)
WO (1) WO2007001476A1 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
EP1151142A2 (en) * 1999-01-28 2001-11-07 Gen-Probe Incorporated Nucleic acid sequences for detecting genetic markers for cancer in a biological sample
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
US20050287068A1 (en) * 2004-06-17 2005-12-29 Bot Adrian I Efficacy of active immunotherapy by integrating diagnostic with therapeutic methods
CA2571168A1 (en) * 2004-06-17 2006-01-26 Mannkind Corporation Mhc i-binding ssx-241-49 variants
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
CA2592972A1 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to bypass cd+4 cells in the induction of an immune response
PL1833506T3 (pl) * 2004-12-29 2016-01-29 Mannkind Corp Zastosowanie kompozycji zawierających różne antygeny związane z nowotworem jako szczepionek przeciwnowotworowych
EP1838338A2 (en) * 2004-12-29 2007-10-03 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
JP2008526763A (ja) * 2004-12-29 2008-07-24 マンカインド コーポレイション 予防又は治療目的のｍｈｃクラスｉ拘束性エピトープに対する免疫応答の誘導、増強及び保持方法
AU2006259221B8 (en) 2005-06-17 2013-02-07 Mannkind Corporation Multivalent entrain-and-amplify immunotherapeutics for carcinoma
SG162817A1 (en) 2005-06-17 2010-07-29 Mannkind Corp Methods and compositions.to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
NZ564359A (en) * 2005-06-17 2011-09-30 Mannkind Corp Analogs of pepetides corresponding to class I MHC-restricted T cell epitopes
CA2646329C (en) 2006-03-20 2018-07-03 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
JP2009544610A (ja) * 2006-07-14 2009-12-17 マンカインド コーポレイション 予防又は治療目的のためにｍｈｃクラスｉ拘束エピトープに対する免疫応答を引き出し、増強し、保持する方法
CA2700436C (en) 2006-09-28 2017-04-18 John S. Yu Cancer vaccines and vaccination methods
WO2009032949A2 (en) 2007-09-04 2009-03-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
EP2227558A1 (en) * 2007-11-30 2010-09-15 GlaxoSmithKline Biologicals SA Method for classifying cancer patients as responder or non-responder to immunotherapy
US20110189093A1 (en) * 2008-04-14 2011-08-04 Proscan Rx Pharma Prostate specific membrane antigen antibodies and antigen binding fragments
US9101537B2 (en) 2008-07-25 2015-08-11 Reven Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
AU2010310468A1 (en) 2009-10-23 2012-05-24 Mannkind Corporation Cancer immunotherapy and method of treatment
EP2569633B1 (en) * 2010-05-14 2016-02-10 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
RU2537263C2 (ru) * 2012-10-22 2014-12-27 Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Нижегородский Государственный Университет Им. Н.И. Лобачевского" Способ скрининга и мониторинга онкологических заболеваний и набор для его осуществления (варианты)
ES2662333T3 (es) 2013-02-14 2018-04-06 Immunocellular Therapeutics Ltd. Vacunas contra el cáncer y métodos de vacunación
US20140234350A1 (en) * 2013-02-14 2014-08-21 Cedars-Sinai Medical Center Ovarian cancer vaccines and vaccination methods
EP3461909A1 (en) * 2013-05-21 2019-04-03 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Isoforms of gata6 and nkx2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy
WO2015070045A1 (en) 2013-11-08 2015-05-14 Baylor College Of Medicine A novel diagnostic/prognostic markers and therapeutic target for cancer
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
KR20230076867A (ko) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
IL294183B2 (en) 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc shared neoantigens
GB201607535D0 (en) * 2016-04-29 2016-06-15 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
US10436771B2 (en) * 2016-04-05 2019-10-08 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for targeted therapy based on single-cell stimulus perturbation response
CA3056212A1 (en) 2016-04-07 2017-10-12 Bostongene Corporation Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
JP7216995B2 (ja) * 2018-12-05 2023-02-02 学校法人関西医科大学 胸腺癌バイオマーカー及び胸腺腫瘍の予後予測マーカー
US12531162B1 (en) * 2023-05-31 2026-01-20 Northeastern University Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net
US12562256B2 (en) * 2023-11-07 2026-02-24 New York University Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940670A (en) * 1986-01-24 1990-07-10 Rhodes Buck A Method for compounding and testing patient specific monoclonal antibodies and monoclonal antibody fragments for in vivo use
US5804381A (en) * 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
DE69334071T2 (de) * 1992-11-05 2007-10-25 Sloan-Kettering Institute For Cancer Research Prostata-spezifisches membranantigen
US5747271A (en) * 1992-12-22 1998-05-05 Ludwig Institute For Cancer Research Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of HLA-A2/tyrosinase derived peptides, and methods for treating said individuals
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5571711A (en) * 1993-06-17 1996-11-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors
US5858689A (en) * 1993-07-22 1999-01-12 Ludwig Institute For Cancer Research Isolated peptides derived from the gage tumor rejection antigen precursor and uses thereof
US5610013A (en) * 1993-07-22 1997-03-11 Ludwig Institute For Cancer Research Method for diagnosing a disorder by determining expression of gage tumor rejection antigen precursors
US6013481A (en) * 1993-07-22 2000-01-11 Ludwig Institute For Cancer Research Isolated, nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof
US5648226A (en) * 1993-07-22 1997-07-15 Ludwig Institute For Cancer Research Isolated peptides derived from tumor rejection antigens, and their use
US5679647A (en) * 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5935818A (en) * 1995-02-24 1999-08-10 Sloan-Kettering Institute For Cancer Research Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US6025191A (en) * 1995-06-07 2000-02-15 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode a melanoma specific antigen and uses thereof
US5856136A (en) * 1996-07-03 1999-01-05 Incyte Pharmaceuticals, Inc. Human stem cell antigens
US6994851B1 (en) * 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6709844B1 (en) * 2000-11-16 2004-03-23 Mannkind Corporation Avoidance of undesirable replication intermediates in plasmid propagation
US20030138808A1 (en) * 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
US6342219B1 (en) * 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
JP3911905B2 (ja) * 1999-04-30 2007-05-09 松下電工株式会社 インパクト回転工具
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
US6861234B1 (en) * 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
US20020048550A1 (en) * 2000-07-20 2002-04-25 Vallera Daniel A. Radiolabeled immunotoxins
US7252824B2 (en) * 2001-03-07 2007-08-07 Mannkind Corporation Anti-neovasculature preparations for cancer
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
CN101024842A (zh) * 2001-11-07 2007-08-29 曼康公司 编码靶相关抗原表位的表达载体及其设计方法
AU2003253860A1 (en) * 2002-07-10 2004-01-23 The Regents Of The University Of Michigan Expression profile of lung cancer
AU2003270311A1 (en) * 2002-09-06 2004-03-29 Mannkind Corporation Epitope sequences
AU2004249254B2 (en) * 2003-06-17 2010-07-08 Mannkind Corporation Combinations of tumor-associated antigens for the treatment of various types of cancers
DK1635863T3 (da) * 2003-06-17 2010-11-22 Mannkind Corp Sammensætninger til udløsning, forbedring og opretholdelse af immunresponser mod MHC-klasse-i-begrænsede epitoper til profylaktiske eller terapeutiske formål
WO2005054508A2 (en) * 2003-12-01 2005-06-16 Ipsogen Gene expression profiling of colon cancer by dna microarrays and correlation with survival and histoclinical parameters
CA2571168A1 (en) * 2004-06-17 2006-01-26 Mannkind Corporation Mhc i-binding ssx-241-49 variants
EP1782070B1 (en) * 2004-06-17 2010-09-08 MannKind Corporation Tumor-associated antigen profiles in cancer diagnostics and immunotherapy
US20050287068A1 (en) * 2004-06-17 2005-12-29 Bot Adrian I Efficacy of active immunotherapy by integrating diagnostic with therapeutic methods

Similar Documents

Publication Publication Date Title
JP2008546687A5 (https=)
JP2008503498A5 (https=)
Esfandiary et al. MAGE-A3: an immunogenic target used in clinical practice
Yamada et al. Next‐generation peptide vaccines for advanced cancer
Sarivalasis et al. A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma
Madan et al. Clinical evaluation of TRICOM vector therapeutic cancer vaccines
Hirayama et al. The present status and future prospects of peptide-based cancer vaccines
Cloosen et al. Expression of tumor-associated differentiation antigens, MUC1 glycoforms and CEA, in human thymic epithelial cells: implications for self-tolerance and tumor therapy
Wu et al. PSCA is a target of chimeric antigen receptor T cells in gastric cancer
Ishikawa et al. Phase I clinical trial of vaccination with LY6K-derived peptide in patients with advanced gastric cancer
Lee et al. Expression of NY-ESO-1 in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and a good prognosis
Funt et al. The role of neoadjuvant trials in drug development for solid tumors
Thor Straten et al. Targetless T cells in cancer immunotherapy
De Pas et al. Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials
McCarthy et al. AE37: a HER2-targeted vaccine for the prevention of breast cancer recurrence
Hale et al. Cancer vaccines: should we be targeting patients with less aggressive disease?
Schneble et al. Peptide-based cancer vaccine strategies and clinical results
Page et al. Emerging immunotherapy strategies in breast cancer
Jafferji et al. Adoptive T-cell therapy for solid malignancies
Dumbrava et al. Abstract OT-03-02: Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors
Tsukahara et al. Peptide vaccination therapy: towards the next generation
Schlom et al. Paradigm shifts in cancer vaccine therapy
Valilou et al. Tumor antigens
Sasada et al. Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines
Khodadoust et al. Tumor antigen discovery through translation of the cancer genome